Association between childhood obesity and use of regular medications in the UK: longitudinal cohort study of children aged 5–11 years by Solmi, F & Morris, S
Association between childhood obesity
and use of regular medications in the
UK: longitudinal cohort study of
children aged 5–11 years
Francesca Solmi, Stephen Morris
To cite: Solmi F, Morris S.
Association between
childhood obesity and use of
regular medications in the
UK: longitudinal cohort study





and additional material is




Received 4 December 2014
Revised 27 April 2015
Accepted 2 May 2015







Objectives: Increasing rates of childhood obesity
have been suggested as a possible cause for the
increasing prevalence of chronic conditions among
adults and children. Few studies have examined
whether obese children are more likely to use
medications than normal weight children. We
investigate this association in the UK.
Design: A panel study with repeated observations at
ages 5, 7 and 11.
Setting: A general population sample drawn from the
Millennium Cohort Study, a UK-based birth cohort.
Participants: A sample of 9667 children.
Primary and secondary outcome measures:
Our primary outcomes were crude and adjusted
probabilities of taking any regular medications and the
number of medications among overweight and obese
children compared with normal weight children. Our
secondary outcome was the distribution of medication
use by therapeutic classification across body mass
index (BMI) groups.
Results: Obese children were more likely to use any
medication (marginal effect (ME)=0.02, 95% CI 0.01 to
0.03) and to use more medications (ME=0.08, 95% CI
0.04 to 0.12) than normal weight children. Obese
children used more medications for respiratory
conditions than those of other BMI groups.
Conclusions: Obese children are more likely to use
regular medications and have comorbid conditions,
even at young ages. This suggests that the cost of
prescriptions should be considered when evaluating
the economic burden of childhood obesity and that
preventative strategies to reduce childhood obesity
could be cost-effective in the short as well as in the long
term. While more research is needed, both clinicians
and policymakers should be aware of these findings
when planning prevention and treatment strategies.
BACKGROUND
The past 30 years have seen a rise in the
prevalence of childhood obesity. Changing
patterns of nutrition and physical activity,
and their interplay with genetic risk factors
could be the main causes of this change.1 In
England it was estimated that, in 2012, 27.9%
of children aged 2–15 years were overweight
or obese compared with 25% in 1995, with a
peak of 34.3% in 2004.2
Childhood obesity is known to persist into
adulthood and to be a risk factor for several
long-term health problems.3 Evidence sug-
gests it is associated with cardiometabolic
(diabetes, hypertension, ischaemic heart
disease, stroke), respiratory (asthma), gynaeco-
logical (polycystic ovary syndrome),4 and mus-
culoskeletal conditions later in life, as well as
physical disability, poor mental health5 and
cancer.4 5 Although the greatest part of the
obesity-related burden of disease is borne by
adults (most disorders associated with obesity
take several years to develop), in recent years
conditions such as hypertension, musculoskel-
etal problems, type 2 diabetes, sleep apnoea
and asthma have become more common
among children,6 suggesting that higher rates
of childhood obesity could be a risk factor for
early onset of chronic conditions.
Strengths and limitations of this study
▪ To the best of our knowledge this is the first
study investigating the association between over-
weight and obesity in children and use of regular
medications.
▪ Our outcome measure was based on the point
prevalence of self-reported use of regular medi-
cations, which could overestimate or underesti-
mate the overall prevalence of medication use in
the sample. We were also unable to measure use
of over-the-counter medications. Our sample
was underpowered to detect differences in use of
medications by therapeutic classification.
▪ We employed a large longitudinal sample of chil-
dren, which allowed us to determine patterns of
medication use across time in different body
mass index groups as well as type of medica-
tions used. Our study provides insight into con-
ditions which could be comorbid with obesity in
childhood.
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The association between obesity in childhood and
adolescence and healthcare use and costs has been
examined in primary studies7–9 and reviews10–12 with
mixed ﬁndings. Most studies found that overweight and
obese children incurred higher healthcare utilisation and
direct costs across different healthcare settings and user
groups.9 13–22 Others did not ﬁnd any differences23 24 or
found higher costs only in females25 or for primary care
consultations.26 Differences in study designs, sample sizes,
care settings, age groups, and healthcare systems make
between-study comparisons difﬁcult. By excluding studies
not including a control group27–29 and not providing
detailed information on cost components,21 25 most
studies examined hospital utilisation and costs,7 8 14 16–
18 20 22 23 26 and primary care consultations.7 8 13 15–20 23 24
Few included pharmacy costs within total healthcare
costs15 or investigated the use of medications9 14 or pre-
scriptions costs9 13 14 22 and thereby reﬂect a trend, also
seen in adult-based studies,30 31 which potentially leads to
an underestimation of obesity-associated healthcare costs.
To date, evidence on higher medication use in over-
weight and obese children compared with children of
normal body mass index (BMI) is mixed, with some
studies ﬁnding differences only in adolescents.9 22 Two
North American studies found that being overweight
or obese was associated with higher costs22 and use9
of prescribed drugs among children and adolescents
aged 12–19 years. An Israeli study found that, while on
average there were no differences between the number
of normal weight and obese children taking medications,
obese children aged 4–7 years, as well as adolescents aged
12–18 years used a higher number of drugs than normal
weight children.14 Similarly, an Australian study found
that children who were obese at age 4–5 had higher pre-
scription expenditures over 5 years.13
Little is also known about differences in prescribed
medication use by therapeutic classiﬁcation across BMI
groups. One study among children in Denmark, the UK
and Italy found that drugs for skin, infectious, and
respiratory conditions were the most commonly pre-
scribed in childhood.32 On the other hand, medications
for the treatment of respiratory conditions,9 20 as well as
those for nervous conditions9 and diabetes,20 have been
found to be common in overweight or obese children.
The paucity of studies investigating type of medication
use among the obese limits our ability to draw conclusive
evidence from existing research.
To date, no UK-based study has investigated the associ-
ation between medication use and obesity among chil-
dren. Therefore, the aim of this study was to examine
this association in children aged 5–11 years in the UK
using data from the Millennium Cohort Study (MCS).
METHODS
Sample
The MCS is a longitudinal cohort of children living in the
UK at 9 months of age, born between 1 September 2000
and 31 August 2001 (for England and Wales), and 24
November 2000 and 11 January 2002 (for Scotland and
Northern Ireland), who were eligible to receive Child
Beneﬁts, which at the time of sampling was a universal
beneﬁt payable to families who were permanent UK resi-
dents.33 The study includes children living in non-
household situations and who were not born in the UK
(but were residing in the UK at recruitment) and,
employed a stratiﬁed clustered framework to ensure
appropriate representation of the disadvantaged and
ethnic minority groups.33 The initial recruited sample con-
sisted of 18 552 families (72% response rate) and 18 818
children, including 246 twins and 10 triplets.33 This was
supplemented by another sample of 692 eligible families
(50% response rate) at MCS2, the second sweep of data
collection which took place in 2004/2005 when the chil-
dren were on average 3 years old, and this resulted in a
total sample of 19 244 families and 19 517 children. More
details on sampling and follow-up of the children can be
found on the study’s website (http://www.cls.ioe.ac.uk).
This study used data from the third (MCS3, 2006),
fourth (MCS4, 2008) and ﬁfth (MCS5, 2012) sweeps of
data collection, which took place when the children were
on average, 5, 7 and 11 years old, respectively. A total of
15 246, 13 857 and 13 287 families and of 15 460, 14 042
and 13 469 children were included at MCS3, MCS4, and
MCS5, respectively. At MCS3, MCS4 and MCS5, 13 251
(85.7%), 11 939 (85.0%) and 11 402 (84.6%) children
had complete data on all variables employed in this study.
Children from Black African and Caribbean, Asian and
other ethnic backgrounds, those whose main respondent
had the lowest education levels or foreign qualiﬁcations,
and those with lower income were more likely to have
incomplete data at every sweep (see online supplementary
table S1). Boys and children whose mother was overweight
or obese at birth were less likely to have complete data at
MCS3 and MCS5, respectively.
A total of 9667 children with complete observations
over the three time-points were included in our ﬁnal
sample. As a sensitivity analysis, we reran our models by
including children who had data for at least one of the
three sweeps of data collection.
Exposure and outcome measures
At each wave, every child’s BMI was calculated from
objective height and weight measurements and cate-
gorised as ‘normal (including underweight)’, ‘over-
weight’, and ‘obese’ using the International Obesity
Task Force age-speciﬁed and gender-speciﬁc BMI
cut-offs.34 The survey’s main respondent was asked if the
study child was currently taking any regular medications,
deﬁned as a medication prescribed by a doctor or a hos-
pital (excluding over-the-counter medications), and
whether these were being taken every day for 2 weeks or
longer. For each child, the question was asked up to
seven times in order to allow for multiple medications.
From these answers we created a binary variable, indicat-
ing whether the child was taking at least one medication
2 Solmi F, et al. BMJ Open 2015;5:e007373. doi:10.1136/bmjopen-2014-007373
Open Access
group.bmj.com on August 20, 2015 - Published by http://bmjopen.bmj.com/Downloaded from 
(1=yes, 0 otherwise), and a continuous variable indicat-
ing the total number of medications taken by the child
(including 0). For each medication, their therapeutic
classiﬁcation was also recorded and grouped according
to the British National Formulary for Children (BNFC)i
chapter codes. A summary binary variable was created to
indicate whether the child was taking at least one medi-
cation from each therapeutic classiﬁcation.
At each wave, the main respondent was asked whether
the child had one or more longstanding illnesses and, if
so, of which types (in MCS3 and MCS4 only). Type of
longstanding illness was coded using International
Classiﬁcation of Diseases, Tenth Revision (ICD-10)
codes; from these we derived broad families of condi-
tions (infections, neoplasms, disorders of the blood,
endocrine system, nervous system, eye, ear, circulatory
system, respiratory system, digestive system, skin, muscu-
loskeletal system and genitourinary system, mental
health disorders, malformation, clinical abnormalities,
injuries or poisoning, or other disorders).
Sociodemographic and socioeconomic covariates
A number of variables (described as time-invariant if
constant across time-points and time-variant if varying at
each time-point) were used in descriptive analyses and
as covariates in multivariate analyses.
Time-invariant variables were: child age at MCS3;
gender; ethnicity (white, Black African or Caribbean,
Asian—Indian, Pakistani, Bangladeshi or other Asian,
mixed, and other backgrounds); main respondent’s
(natural mother for 99.9% of children at MCS1) highest
academic qualiﬁcation at MCS1 (no qualiﬁcation;
General Certiﬁcate of Secondary Education (GCSE)—
obtained at age 16, or A levels—obtained at age 17–18;
diploma of higher education; degree or higher; and any
foreign qualiﬁcations); natural mother’s BMI at MCS1
(pregnant; underweight, normal weight, obese). The
last variable was included based on evidence of a positive
association between maternal and child BMI,35 and as
maternal obesity is a risk factor for chronic illness in the
child.36 37 Since data on natural mother’s BMI was not
available at MCS5, we only included values collected at
MCS1 given their high correlation with those collected
at MCS3 and MCS4 (r=0.87 and r=0.85, respectively).
Time-variant variables were: weekly family income equiv-
alised using Organisation for Economic Co-operation and
Development (OECD) weights (included as a continuous
variable) and an indicator for sweep of data collection in
order to account for secular and age-related trends.
Data analyses
Children with complete data on exposure (BMI),
primary outcomes (at least 1 medication, number of
medications) and potential confounding factors for the
association between BMI and medication use at MCS3,
MCS4 and MCS5 (age, gender, maternal BMI, main
respondent education, income) were included in the
ﬁnal sample. The sample with data from the three waves
of data collection was described with respect to sociode-
mographic and socioeconomic characteristics by using
cross-tabulations and analysis of variance (ANOVA).
Our primary outcomes were: (1) a binary variable
indicating whether the child used at least one medica-
tion (1=yes, 0 otherwise); (2) a count variable for the
total number of medications taken by the child (includ-
ing 0). The ﬁrst outcome was investigated with a random
effects logit regression model; the second, by using a
random effects negative binomial regression model. The
latter was used instead of Poisson regression because our
data were overdispersed (mean medications per child:
0.19, variance: 0.38).38 Random effects were employed
under the assumption that unobserved variables were
time-invariant, and within-subject variability with respect
to the time-variant variables included in the model was
small. Under these assumptions, SEs produced by a
ﬁxed-effect model would have been overestimated.
For both outcomes, we ﬁtted a crude (unadjusted)
and an adjusted model, the latter controlling for poten-
tial confounding factors described above. We also ran a
model ﬁtting an interaction between BMI and income, a
proxy for socioeconomic status, in order to test for non-
linear relationships between the two variables. We report
marginal effects (ME) holding the unobserved effect at
zero, showing the impact of overweight and obesity on
the probability of medication use and on the number of
medications used, compared with normal weight.
As secondary outcomes, we investigated the association
between overweight and obesity, and type of longstand-
ing illness in the child and medication used by doing
cross-tabulations and χ2 tests on pooled data from MCS3
MCS4 and MCS5. Given the low numbers of longstand-
ing illnesses and medication use in different therapeutic
categories, and the lack of statistical power we did not ﬁt
regression models for individual therapeutic categories.
We grouped therapeutic categories of medications
according to those which obese children were more
likely to use (medications for respiratory, nervous system
and endocrine disorders) and unlikely to use (all the
remaining categories) based on previous studies,9 20 and
ran univariate and multivariate regression models of
their association with child BMI category.
The presence of longstanding illness was not included
in regression models on the basis that this is on the
causal pathway between obesity and medication use.
Longstanding illnesses among parents were also not
iThe BNFC (http://www.bnf.org) is a reference manual providing
advice to healthcare professionals about prescribing, dispensing,
monitoring and administering medicines to children. It has chapters
categorising medications into the therapeutic classiﬁcations employed
in this study—01: gastrointestinal system; 02: cardiovascular system; 03:
respiratory system; 04: central nervous system; 05: infections; 06:
endocrine system; 07: obstetrics, gynaecology & urinary tract disorders;
08: malignant disease and immunosuppression; 09: nutrition and
blood; 10: musculoskeletal and joint diseases; 11: eye; 12: ear, nose and
oropharynx; 13: skin.
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included for similar reasons, as they could be associated, via
genetic risk factors, to longstanding illnesses in the child.
All analyses were run using Stata V.13.39
RESULTS
Sample characteristics
A total of 9667 children were included in the ﬁnal
model. The majority of children were of white ethnicity
and had a main respondent educated up to GCSE or A
level standard or higher (table 1). More children from
lower socioeconomic status groups (ie, lower income
and lower levels of main respondent’s education) as well
as children belonging to an ethnic minority had incom-
plete data at all three waves of data collection; more chil-
dren whose mother was overweight had incomplete data
at MCS4 (see online supplementary table S1).
In MCS3, MCS4 and MCS5, 15.2%, 13.8% and 20.6%
of children were overweight and 5.0%, 5.3% and 6.1%
were obese, respectively (table 2). Our longitudinal
sample consisted of 29 001 observations of whom 16.5%
and 5.4% corresponded to a time-point in which the
child was overweight or obese, respectively (table 1).
More girls than boys were overweight and obese.
Children of black, Asian and mixed ethnic backgrounds
were also more likely to be obese, as were: children whose
main respondent had no educational qualiﬁcations or
qualiﬁcations up to GCSEs or A levels; children whose
mother was overweight or obese at MCS1; and children
who had at least one longstanding illness (table 1).
Overall medication use was 12.2% (table 2). A total of
11.7%, 13.0% and 17.8% of children in the normal
weight, overweight and obese groups, respectively, took a
medication, of whom 55.6%, 78.4% and 77.2%, respect-
ively, did so at all three waves (table 2). Mean number of
medications used was 0.18 (SD 0.6) for children of
normal BMI, 0.21 (SD 0.6) for overweight children, and
0.31 (SD 0.8) for obese children (table 1).
The prevalence of longstanding illness was highest in
children who were obese (22.0%; table 1). At age 5
(MCS3), obese children had higher proportions of
endocrine, respiratory, and mental health conditions as
well as problems with the digestive system and clinical
complications. At age 7, the most prevalent conditions
among children who were obese were respiratory condi-
tions and neoplasms (see online supplementary table S3).
Respiratory conditions were the most prevalent at both
ages among obese children (12.3% at age 5 and 11.5%
at age 7) compared with normal weight children (7.4%
at age 5 and 6.8% at age 7).
Association between BMI category and medication use
In crude regression models (table 3), children who were
overweight (ME=0.006, 95% CI 0.001 to 0.011) and
obese (ME=0.023, 95% CI 0.011 to 0.035) were more
likely to take at least one medication and to take a
higher number of medications (overweight=ME=0.033,
95% CI 0.012 to 0.053; obese=ME=0.100, 95% CI 0.057
to 0.143) compared with children who were of normal
weight. In adjusted models, obese children remained
more likely to take at least one medication (ME=0.016,
95% CI 0.005 to 0.027) and to take a higher number of
medications (ME=0.075, 95% CI 0.035 to 0.115). No dif-
ferences were found between overweight and normal
weight children in the likelihood of taking at least one
medication, although a strong association was found
with respect to overweight children taking more medica-
tions than normal weight children (ME=0.021, 95% CI
0.001 to 0.041). In multivariate analyses, we found some
evidence of an independent association between mater-
nal obesity and increased use of medication, and strong
evidence for an association between high levels of main
respondent’s education, and lower use of medications
and number of medications (table 3). Results were
similar when we reran our models by including children
who had data for at least one sweep of data collection
(see online supplementary table S2). None of the inter-
actions between income and BMI group was signiﬁcantly
different to zero in any of the models, and including the
interaction terms did not change the size or the signiﬁ-
cance of the coefﬁcients of any of the other variables
included in the analyses (detailed results not shown).
Association between BMI category and medication use by
therapeutic classification
Medications for respiratory (5.6%), skin (1.1%) and
central nervous system (0.8%) disorders were most com-
monly used (table 4). Use of medications from other
therapeutic categories was low (all <0.8%). Overweight
and obese children had greater use of medications for
respiratory conditions and overweight children had
greater use of medications to treat infections. Obesity,
but not overweight, had a strong association with greater
use of medications for respiratory, endocrine and
central nervous system disorders combined (ME=0.008,
95% CI 0.003 to 0.013), but not for all the other condi-
tions combined (table 3). These results were unchanged
after including an interaction term between BMI and
income, which was non-signiﬁcant (results not shown).
DISCUSSION
We investigated the association between overweight and
obesity, and medication use in children aged 5–11 years.
We found that, overall, 12.2% of children used prescribed
medications regularly, although children who were obese
had a higher probability of using at least one regular medi-
cation and a higher number of medications compared
with children of normal BMI. We also found that over-
weight and obese children were more likely to use medica-
tions for respiratory, endocrine and central nervous system
diseases, which are potentially related to obesity.
Research on the use of prescription drugs in children
is scarce and differences in study methodologies make
direct comparisons difﬁcult. To our knowledge, only one
study has addressed prevalence of medication use at this
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Table 1 Sociodemographic, socioeconomic, biological and health-related differences across BMI groups for all three sweeps














Total 29 001 (100) 22 624 (78.1) 4801 (16.5) 1576 (5.4) N/A
Gender
Male 14 496 (49.9) 11 593 (51.2) 2163 (45.1) 740 (47.0) <0.0001
Female 14 505 (50.1) 11 031 (48.8) 2638 (54.9) 836 (53.0)
Ethnicity
White 25 287 (87.2) 19 831 (87.7) 4163 (86.7) 1293 (82.0) <0.0001
Mixed 727 (2.5) 529 (2.3) 131 (2.7) 57 (3.6)
Black African/Caribbean 579 (2.0) 347 (1.5) 155 (3.2) 77 (4.9)
Asian 2049 (7.1) 1619 (7.2) 300 (6.3) 130 (8.3)
Other 369 (1.2) 298 (1.3) 52 (1.1) 19 (1.2)
Main respondent’s highest education (MCS1)
None 3951 (13.6) 2988 (13.2) 675 (14.0) 288 (18.3) <0.0001
GCSE/A levels 15 777 (54.4) 12 069 (53.4) 2786 (58.0) 922 (58.5)
Diploma higher education 2895 (10.0) 2272 (10.0) 473 (10.0) 150 (9.5)
Degree or higher 5754 (19.8) 4805 (21.2) 784 (16.3) 165 (10.4)
Foreign qualification 624 (2.2) 490 (2.2) 83 (1.7) 51 (3.2)
Natural mother’s BMI (MCS1)
Pregnant 1311 (4.5) 1038 (4.6) 220 (4.6) 53 (3.4) <0.0001
Underweight 1077 (3.7) 973 (4.3) 89 (1.9) 15 (0.9)
Normal weight 15 840 (54.6) 13 283 (58.7) 2054 (42.8) 503 (31.9)
Overweight 7158 (24.7) 5114 (22.6) 1542 (32.1) 502 (31.8)
Obese 3615 (12.5) 2216 (9.8) 896 (18.7) 503 (32.0)
Child currently taking at least one regular medication
No 25 443 (87.7) 19 972 (88.3) 4175 (87.0) 1296 (82.2) <0.0001
Yes 3558 (12.3) 2652 (11.7) 626 (13.0) 280 (17.8)
Number of medicines
0 25 443 (87.7) 19 972 (88.3) 4181 (87.0) 1296 (82.2) <0.0001
1 2178 (7.5) 1651 (7.2) 372 (7.7) 155 (9.8)
2 918 (3.2) 662 (2.9) 177 (3.6) 79 (5.0)
3 309 (1.0) 233 (1.0) 48 (1.0) 28 (1.8)
4 84 (0.3) 59 (0.3) 15 (0.3) 10 (0.6)
5 35 (0.1) 23 (0.1) 8 (0.2) 4 (0.3)
6 24 (0.1) 17 (0.1) 4 (0.1) 3 (0.2)
7 10 (0.1) 7 (0.1) 2 (0.1) 1 (0.1)
Longstanding illness
No 24 148 (83.3) 18 887 (83.5) 4033 (84.0) 1228 (78.0) <0.0001
Yes 4853 (16.7) 3737 (16.5) 768 (15.0) 348 (22.0)
Sweep
MCS3 9667 (33.3) 7718 (34.1) 1473 (30.7) 476 (30.2) <0.0001
MCS4 9667 (33.3) 7819 (34.6) 1337 (27,9) 511 (32.4)







Mean (SD) p (F)




352.5 (200.1) 359.0 (203.8) 337.0 (186.9) 308.0 (174.7) <0.0001
Number of medications 0.20 (0.62) 0.18 (0.60) 0.21 (0.64) 0.31 (0.79) <0.0001
BMI, body mass index; GCSE, General Certificate of Secondary Education; MCS, Millennium Cohort Study; N/A, not applicable; OECD,
Organisation for Economic Co-operation and Development.
Solmi F, et al. BMJ Open 2015;5:e007373. doi:10.1136/bmjopen-2014-007373 5
Open Access
group.bmj.com on August 20, 2015 - Published by http://bmjopen.bmj.com/Downloaded from 
age in the UK,32 but it did not investigate whether there
were differences across BMI categories. We found that
obese and, to a lesser extent, overweight children had a
higher probability of using prescription drugs. Our ﬁnd-
ings are consistent with some non-UK studies,8 27 but
not others.9 14 Differences in exposure deﬁnition, study
design and sample size may account for any discrepan-
cies. Kuhle et al9 found that overweight or obese
Canadian adolescents, but not children, had a higher
prescription drug use than those who were normal
weight. We found an effect in obese, but not overweight
children, and it is possible that combining overweight
and obese BMI categories may have diluted the effect in
the Canadian study. This study also employed a cross-
sectional design, which could underestimate medication
use compared with a repeated observation design, since
obese children were likely to use medications at all time-
points in MCS. An Israel-based study found no variation
in use of medications between children in different
obesity groups, but it did ﬁnd a higher number of medi-
cation used by obese children compared with normal
weight children.14 Although this study assessed medica-
tion use over a longer time period and more accurately
through the use of medical records, the much smaller
sample size (363 obese children, 382 normal weight chil-
dren) could have resulted in type II error, explaining
the lack of a signiﬁcant association between obesity and
medication use.
Obesity is associated with several long-term conditions
which usually occur later in life3 and it has been shown
that English adults who are obese are more likely to use
prescription drugs for cardiovascular, gastrointestinal,
respiratory, central nervous system and endocrine condi-
tions, and gynaecological and musculoskeletal disor-
ders.31 Recent evidence suggests that the prevalence of
some of these conditions in children is rising as a
consequence of obesity.6 By observing higher use of
medications for speciﬁc therapeutic classiﬁcations of
drugs in children who were obese, our ﬁndings appear
to provide some evidence in support of these ﬁndings.
We found a strong association between childhood
obesity and use of any medication for respiratory, endo-
crine and central nervous system conditions, which have
been previously identiﬁed as ‘at risk’ therapeutic cat-
egories for obese children.9 20 Based on simple associa-
tions, this ﬁnding may be driven predominantly by an
association between obesity and use of medications for
disorders of the respiratory system; notably, we found
that almost twice as many obese children compared with
normal weight ones used medications for respiratory
conditions, which has been previously documented.9
The positive association between asthma and obesity in
childhood is one which has received growing attention
in recent years and good evidence exists on the associ-
ation between the two although causal patterns remain
unclear.40 41 Our ﬁndings suggest that obese children
are more likely to suffer from comorbid respiratory con-
ditions and thus, incur higher healthcare expenditures.
A better understanding of the aetiology of this
comorbidity is warranted to devise cost-effective policies
for the prevention and management of these conditions
in childhood.
The presence of a socioeconomic gradient in the dis-
tribution of childhood obesity has been previously docu-
mented in the literature.42 43 In our sample, a greater
proportion of children who were obese had lower family
income, lower levels of main respondent’s education,
and belonged to ethnic minorities. This reﬂected in
both lower ME for the association between child BMI
and use of medications, once these factors were
accounted for in multivariate analyses, and in an inde-
pendent association between lower parental education
Table 2 Proportion of children with normal, overweight and obese BMI at each of the three waves of data collection
(N=9667, MCS3, MCS4, MCS5) and distribution of medication use (using at least 1 medication) in the whole longitudinal





















Overall 9667 (100) 9667 (100) 9667 (100)
No – – – 25 443 (87.8) 9311 (96.3) 91.1
Yes – – – 3558 (12.2) 2294 (23.7) 51.7
Normal weight 7718 (79.8) 7819 (80.9) 7087 (73.3)
No – – – 19 972 (88.3) 8146 (95.4) 92.4
Yes – – – 2652 (11.7) 1809 (21.2) 55.6
Overweight 1473 (15.2) 1337 (13.8) 1991 (20.6)
No – – – 4175 (87.0) 2693 (90.0) 96.4
Yes – – – 626 (13.0) 509 (17.0) 78.4
Obese 475 (5.0) 511 (5.3) 589 (6.1)
No – – – 1296 (82.2) 792 (87.7) 94.7
Yes – – – 280 (17.8) 198 (22.0) 77.2
BMI, body mass index; MCS, Millennium Cohort Study.
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Table 3 Association between overweight and obese BMI (vs normal BMI) and use of medications
Outcome
Taking ≥1 regular prescriptions Number of regular prescriptions ≥1 High-risk medication† ≥1 Low-risk medication‡
BMI group Crude ME (95% CI) Crude ME (95% CI) Crude ME (95% CI) Crude ME (95% CI)
BMI
Normal weight Ref. Ref. Ref. Ref.
Overweight 0.006 (0.001 to 0.011)** 0.033 (0.012 to 0.053)** 0.002 (0.001 to 0.004)** 0.001 (0.001 to 0.003)
Obese 0.023 (0.011 to 0.035)** 0.100 (0.057 to 0.143)** 0.010 (0.005 to 0.016)** −0.001 (−0.003 to 0.003)
Adjusted ME§ (95% CI) Adjusted ME§ (95% CI) Adjusted ME§ (95% CI) Adjusted ME§ (95% CI)
BMI
Normal weight Ref. Ref. Ref. Ref.
Overweight 0.002 (−0.002 to 0.007) 0.021 (0.001 to 0.041)** 0.001 (−0.001 to 0.003) 0.001 (−0.001 to 0.003)
Obese 0.016 (0.005 to 0.027)** 0.075 (0.035 to 0.115)** 0.008 (0.003 to 0.013)** −0.001 (0.003 to 0.02)
Age at first sweep
4 Ref. Ref. Ref Ref
5 0.002 (−0.004 to 0.008) 0.008 (−0.017 to 0.033) 0.001 (−0.001 to 0.003) −0.001 (−0.002 to 0.001)
6 −0.02 (−0.047 to 0.011) −0.101 (−0.258 to 0.057) −0.004 (−0.017 to 0.007) 0.001 (−0.020 to 0.020)
Sweep
MCS3 Ref. Ref. Ref Ref
MCS4 0.011 (0.008 to 0.014)** 0.054 (0.042 to 0.067)** 0.002 (0.001 to 0.003)** 0.001 (−0.001 to 0.002)
MCS5 0.022 (0.014 to 0.031)** 0.089 (0.076 to 0.104)** 0.011 (0.007 to 0.015)** 0.002 (0.001 to 0.003)**
Maternal BMI
Pregnant Ref. Ref. Ref. Ref.
Underweight 0.009 (−0.008 to 0.026) 0.054 (−0.026 to 0.133) 0.004 (−0.003 to 0.011) −0.001 (−0.004 to 0.003)
Normal weight −0.002 (−0.012 to 0.008) −0.016 (−0.065 to 0.033) −0.001 (−0.006 to 0.003) 0.001 (−0.001 to 0.004)
Overweight 0.002 (−0.009 to 0.013) 0.016 (−0.036 to 0.067) 0.001 (−0.004 to 0.005) 0.002 (−0.001 to 0.005)
Obese 0.013 (−0.001 to 0.026)* 0.047 (−0.011 to 0.105) 0.005 (−0.001 to 0.010)* 0.001 (−0.002 to 0.004)*
Gender
Male Ref. Ref. Ref. Ref.
Female −0.012 (−0.017 to −0.008)** −0.060 (−0.081 to −0.040)** −0.007 (−0.009 to −0.005)** 0.001 (−0.001 to 0.002)
Education
None Ref. Ref. Ref. Ref.
GCSE/A level −0.005 (−0.013 to 0.003) −0.012 (−0.045 to 0.021) −0.004 (−0.007 to −0.001)** 0.002 (0.001 to 0.004)**
Diploma higher education −0.003 (−0.013 to 0.009) −0.009 (−0.054 to 0.036) −0.002 (−0.006 to 0.002) 0.002 (−0.001 to 0.005)
Degree or higher −0.012 (−0.019 to −0.003)** −0.030 (−0.068 to 0.008)** −0.004 (−0.008 to −0.001)** 0.001 (−0.002 to 0.002)
Foreign qualification −0.004 (−0.021 to 0.019) −0.029 (−0.100 to 0.041) −0.006 (−0.011 to −0.001)** 0.001 (−0.004 to 0.004)
Ethnicity
White Ref. Ref. Ref. Ref.
Mixed 0.017 (−0.003 to 0.036) 0.056 (−0.026 to 0.140) 0.002 (−0.005 to 0.008) 0.002 (−0.003 to 0.007)
Black African/Caribbean 0.001 (−0.015 to 0.016) 0.009 (−0.066 to 0.084) −0.001 (−0.006 to 0.006) −0.001 (−0.005 to 0.004)
Asian 0.007 (−0.004 to 0.016) 0.002 (−0.038 to 0.043) −0.001 (−0.004 to 0.002) 0.002 (−0.001 to 0.006)
Other 0.001 (−0.019 to 0.019) −0.041 (−0.115 to 0.033) −0.002 (−0.009 to 0.005) −0.002 (−0.007 to 0.003)
OECD equivalised income −0.001 (−0.001 to 0.001) −0.001 (−0.001 to 0.001) −0.001 (−0.001 to 0.001)* 0.001 (−0.001 to 0.001)
**p<0.05; *0.1>p>0.05.
†High-risk medications: medications for respiratory, central nervous system and endocrine conditions.
‡Low-risk medications: medications for gastrointestinal, cardiovascular, infections, obstetric, malignant, nutrition and blood, musculoskeletal, ear, eye and skin conditions.
§Adjusted: age, gender, ethnicity, main respondent education, OECD equivalised income, natural mother’s BMI.




























and higher use of medications. Although we were not
able to discriminate in this study as to whether a change
in trend has occurred over time, a previous study using
data from the Health Survey for England has shown
that, while the prevalence of childhood obesity in
England had been reduced during the years in which
MCS had also taken place, its socioeconomic gradient
had not42 and our ﬁndings seem to conﬁrm this result.
Since children from low socioeconomic status appear to
be more vulnerable to obesity, policies and educational
programmes aimed at reducing lifestyle risk factors for
obesity (such as sedentary lifestyle and poor nutrition)
targeting families with low level of literacy are warranted
to reduce both the short-term and long-term health and
economic impact of childhood obesity.
We also found an independent association between
maternal obesity and higher use of medications in the
child. This suggests that maternal obesity could signal
morbidity in the mother, which could be passed on to
the child by means of genetic predisposition. However,
we also found an association between maternal and
child obesity, conﬁrming previous ﬁndings lending
support to the hypothesis of an intergenerational trans-
mission of obesity.35 44 45 Since both childhood obesity














None 28 841 (99.4) 22 503 (99.5) 4773 (99.4) 1565 (99.3) 0.6
At least one 160 (0.6) 121 (0.5) 28 (0.6) 11 (0.7)
Cardiovascular
None 28 986 (99.9) 22 613 (99.9) 4797 (99.9) 1576 (100.0) 0.4
At least one 15 (0.1) 11 (0.1) 4 (0.1) 0 (0.0)
Respiratory
None 27 383 (94.4) 21 450 (94.8) 4507 (93.9) 1426 (90.5) <0.0001
At least one 1618 (5.6) 1174 (5.2) 294 (6.1) 150 (9.5)
Central nervous system
None 28 784 (99.2) 22 454 (99.2) 4769 (99.3) 1561 (99.0) 0.5
At least one 217 (0.8) 170 (0.8) 32 (0.7) 15 (1.0)
Infections
None 28 920 (99.7) 22 567 (99.8) 4779 (99.5) 1574 (99.9) 0.02
At least one 81 (0.3) 57 (0.2) 22 (0.5) 2 (0.1)
Endocrine
None 28 896 (99.6) 22 550 (99.7) 4780 (99.6) 1534 (99.4) 0.09
At least one 105 (0.4) 74 (0.3) 21 (0.4) 10 (0.6)
Obstetrics
None 28 972 (99.9) 22 602 (99.9) 4797 (99.9) 1573 (99.4) 0.5
At least one 29 (0.1) 22 (0.1) 4 (0.1) 3 (0.2)
Malignant disease
None 28 994 (99.9) 22 621 (99.9) 4798 (99.9) 1575 (99.94) 0.08
At least one 7 (0.02) 3 (0.01) 3 (0.1) 1 (0.06)
Nutrition and blood
None 28 946 (99.8) 22 580 (99.8) 4793 (99.8) 1573 (99.8) 0.9
At least one 55 (0.2) 44 (0.2) 8 (0.2) 3 (0.2)
Musculoskeletal
None 28 986 (99.9) 22 613 (99.9) 4797 (99.9) 1576 (100.0) 0.4
At least one 15 (0.1) 11 (0.1) 4 (0.1) 0 (0.0)
Eye
None 28 990 (99.9) 22 615 (99.96) 4799 (99.96) 1576 (100.0) 0.7
At least one 11 (0.1) 9 (0.04) 2 (0.04) 0 (0.0)
Ear–nose
None 28 918 (99.7) 22 563 (99.7) 4785 (99.7) 1570 (99.6) 0.6
At least one 83 (0.3) 61 (0.3) 16 (0.3) 6 (0.4)
Skin
None 28 687 (98.9) 22 381 (98.9) 4748 (98.9) 1558 (98.1) 0.9
At least one 314 (1.1) 243 (1.1) 53 (1.1) 18 (1.1)
Total numbers of medications do not add up to those in table 3 due to missing values on the type of medication variable.
BMI, body mass index; MCS, Millennium Cohort Study.
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and maternal BMI emerged as strong predictors of
medication use in childhood policies aimed at curbing
obesity in the child could have the potential for lowering
the risk in children who might be genetically predis-
posed to this disease.
This study has several strengths. First, it is the ﬁrst to
investigate the association between obesity and medica-
tion use in childhood in the UK. We used a large repre-
sentative longitudinal sample of children that was
followed over three time-points at ages 5, 7 and 11.
We were, therefore, able to determine patterns of medi-
cation use across time in different BMI groups. As well
as employing child’s use of any medications as outcome
in our analyses, we were also able to investigate the
number and type of medications used, which provided
some insight on which conditions might be more
frequently comorbid with obesity in childhood. Finally,
we were able to adjust for other variables, which could
have potentially confounded the association being
investigated.
Nevertheless, some limitations also need to be
acknowledged. This study relies on point prevalence of
self-reported medication use by the main household
respondent which could overestimate or underestimate
the prevalence of our outcome and, thus, of its associ-
ation with the exposure under investigation. The study
also only included prescribed medications taken by the
child every day for at least 2 weeks, which could result in
an underestimation of total medication use in the
sample, for example, by not including over-the-counter
medications and by requiring use every day for at least
2 weeks. Our sample was underpowered to detect differ-
ences in use of medications by therapeutic classiﬁcation,
given the low use of some types of medication in this
age group. However, we were able to group medications
that are likely to be related to obesity. More research
using primary and secondary care registers and a longer
time series is warranted in order to provide more accur-
ate estimates. We found selective attrition with respect to
children from low socioeconomic status at all waves of
data collection. Since we found some evidence of a gra-
dient in socioeconomic status and both obesity and
medication use this means that we could be underesti-
mating this association in our study. We included under-
weight in our normal BMI category; this could lead to
an underestimation of the association with medication
use as underweight children might be more likely to be
ill. We attempted to use a ﬁrst-differences approach,
regressing change in taking medication between sweeps
on change in BMI group, but the majority of children
(>85%) were classiﬁed as either normal weight or over-
weight/obese in all three sweeps. We could not employ
survey weights given the panel structure of the data;
therefore, some of the effects of confounding variables,
such as ethnicity, on the association between exposure
and outcome could have been missed in our analyses.
Finally, in our study we evaluated associations only, and
were not able to identify causal effect of obesity on
medication use. For example, it may be that medication
use affects obesity or that there are unobserved factors,
such as time preference, that affect both medication use
and obesity. Further research to identify causal effects,
for example, using instrumental variable regression tech-
niques, would be beneﬁcial.
In conclusion, obese children in the UK are more
likely to use prescribed medications conﬁrming that
these costs should be considered when evaluating the
cost of childhood obesity. Our ﬁndings also suggest that
even at young ages, obesity is associated with a number
of comorbid conditions, with some evidence of a socio-
economic gradient in this association. More research
aimed at capturing both intergenerational and environ-
mental risk factors for obesity and medication use as
well as healthcare use and its associated costs in children
is needed as a starting point for devising cost-effective
prevention strategies, and analyses investigating the costs
of childhood obesity should include the costs of medica-
tion use as well as other healthcare costs.
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